Member Info for Asleep

Very encouraging Q1 Trading statement with a 19% increase in revenue compared with the same quarter last year. Therefore, I am predicting a 23% revenue incease on the Quarter One performance moving from £155.3m to £186m in Quarter 2. I am basing this on the continued upward momentum in revenue generation, opening new markets and the fact that the lockdown period may have increased the number of users and the amount spent per user is likely to have risen also. I hope we get an update soon to clarify my prediction.

A small pull back is good for the general upward momentum shown by the share price chart.

Looking forward to some positive news here soon.

I'm a vegetarian so I will be ok!

Confirmation of imminent news shortly

I believe you are right Dufry, we need some solid contractual revenue generating numbers to propel Hemo upwards. This could well come soon with the GlobalCo agreement plus any other Covid or Mice numbers. I believe the downside risks are small compared to the upside potential, however that depends on the price you purchased at! A price below 6p is a good entry point considering the near future newsflow which we all hope will be positive and have monetary figures attached.

Do any of you invest in gold through other vehicles such as ETF's or physical gold coins/bars? If so have these investments been fruitful or would you recommend them?

A £1.23 all share offer seems paltry compared to the share price now, good move to turn the offer down, Endevour would have gained CEY on the cheap.

Thanks, I will keep a low profile and watch and learn!

Having read the thoughtful and well researched posts in here and looked at company fundamentals I have dipped my toe into CEY. Wish me Luck!

https://www.youtube.com/watch?v=6kG7G_Hwo9U

Just a reminder this video is from 2017 and explains how transformational Vlad's Cornell University research for a replacement for chemo actually actaully is. Now skip forward 2.5 yrs to now and reflect on the developments being made with GlobalCo., Patents granted, etc etc.

Is there a remote possibility that Hemo mice might have been used in the AZD1222 SARS-CoV-2 vaccine currently being tested by AZN/Oxford University?
I have seen that mice were used alongside monkeys for testing purposes.

https://www.proactiveinvestors.co.uk/companies/news/922835/888-holdings-plc-full-year-profits-to-top-expectations-after-sales-jump-during-pandemic-922835.html

Expecting a 15% rise from £9 which should take the share price above £10.

https://www.ft.com/content/80a21ca2-136b-11e9-a581-4ff78404524e

Hemogenyx is surely a small biotech which would fit the needs of a big pharma. We are already seeing Hemo devlop callobarations so far with 'GlobalCo', Johson & Johnson, Orgenesis and Lakepharma and possible others that we are unaware of. Big Pharma should realise the speed at which new drugs can be researched by Hemo, its unique mice benefits, the expertise of its personnel and its successful developments so far. So hold tight watch the share price rise until big pharma have no choice but to take notice with maybe a few companies wanting to acquire the company leading to a bidding war. First it will start with a cheeky bid maybe £250m, other companies will see this low offer and think 'we can't let that happen and bid up to £1bn in response. That' my view anyway.

I with you all the way up to that price JHFH.

Except its raining in Darlo!

Let's hope he doesn't sell for £50m, far to cheap for 11.5p a share or £100m at 22p.

I am sure that the RNS is worth more than the above increase with what the RNS implies by closer developments and agreements with the 'GlobalCo'.

Nice one JHFH, showing great confidence in HEMO. Thanks for your analysis yesterday showing MM signals. Really helpful. Asleep